MONMOUTH JUNCTION, N.J., Aug. 18, 2022 /PRNewswire/ — Tris Pharma, Inc. (“Tris”) a fully integrated pharmaceutical company with a robust portfolio of CNS products announced today the decision by the US District Court for the District of New Jersey to uphold the validity of various…
Tris Pharma Announces US District Court Upholds Validity of QuilliChew ER® Patents; Rules Teva Infringes Tris Patents
Aug 18, 2022 | Uncategorized